Lupus Diagnostic Criteria
The EULAR/ACR 2019 classification criteria for systemic lupus erythematosus require a positive ANA test (titer ≥1:80 by indirect immunofluorescence on HEp-2 cells) as an obligatory entry criterion, followed by accumulation of ≥10 points from weighted clinical and immunological domains. 1, 2
Entry Criterion: ANA Testing
The most significant change in the 2019 criteria is establishing positive ANA as a mandatory entry requirement before any other criteria can be counted 1. This represents a strategic shift from previous classification systems where ANA had equal weight with other autoantibodies.
Key specifications for ANA entry:
- Must be positive at titer ≥1:80 by indirect immunofluorescence test (IFI) on HEp-2 cells 1
- Needs to be positive at least once in the patient's history 2
- Without positive ANA, classification as SLE is not possible under these criteria
Critical Caveat About ANA Specificity
The 1:80 ANA cutoff has only 74.7% specificity for SLE (95% CI: 66.7%-81.3%), meaning it generates many false positives 1. This is substantially lower than the 93.4% specificity achieved when using the complete EULAR/ACR 2019 criteria set 1.
For unselected populations, consider using 1:160 as the cutoff, which increases specificity to 86.2% while maintaining 95.8% sensitivity 1. The 1:80 threshold works best as a screening tool that triggers further evaluation, not as a standalone diagnostic marker.
The Point System: Weighted Domains
After meeting the ANA entry criterion, patients accumulate points from 7 clinical domains and 3 immunologic domains 2, 3:
Clinical Domains (weighted 2-10 points):
- Constitutional: Non-infectious fever (2 points)
- Hematologic: Leukopenia, thrombocytopenia, autoimmune hemolysis (2-4 points)
- Neuropsychiatric: Delirium, psychosis, seizure (2-5 points)
- Mucocutaneous: Alopecia, oral ulcers, subacute/chronic cutaneous lupus, acute cutaneous lupus (2-6 points)
- Serosal: Pleural/pericardial effusion or acute pericarditis (5-6 points)
- Musculoskeletal: Joint involvement (6 points)
- Renal: Proteinuria >0.5g/24h, renal biopsy showing Class II or V lupus nephritis (4-8 points), or Class III or IV lupus nephritis (10 points - sufficient alone for classification) 2, 3
Immunologic Domains (weighted 2-6 points):
- Antiphospholipid antibodies: Anticardiolipin, anti-β2GP1, or lupus anticoagulant (2 points)
- Complement proteins: Low C3 or low C4 (3-4 points)
- SLE-specific antibodies: Anti-dsDNA or anti-Smith (6 points) 2, 4
Scoring Rules
Within each domain, only count the highest-weighted criterion - do not add multiple items from the same domain 2, 3. For example, if a patient has both oral ulcers (2 points) and acute cutaneous lupus (6 points), only count the 6 points.
The critical attribution rule: Only count criteria that are attributable to SLE and not better explained by another diagnosis 2, 3. This single rule replaces the multiple exclusions from previous criteria sets.
Classification threshold: ≥10 points 2, 4
Confirmatory Testing Strategy
When ANA is positive, confirmatory anti-ENA testing is recommended 1. The most common autoantibody targets in SLE include anti-dsDNA, anti-Smith, anti-Ro, anti-La, anti-RNP, anti-chromatin, and anti-ribosomal P 1.
For anti-dsDNA testing specifically, use a double-screening strategy 1:
- First: Solid-phase assay (FEIA, CLIA, or ELISA) - high sensitivity
- Second: Crithidia luciliae immunofluorescence test (CLIFT) for confirmation - high specificity, considered pathognomonic
If the solid-phase assay is negative and clinical suspicion is low, report as negative anti-dsDNA without performing CLIFT 1. Only proceed to CLIFT if clinical suspicion remains high despite negative screening.
If solid-phase is positive but CLIFT is negative: This common scenario neither confirms nor excludes SLE. Consider testing for anti-nucleosome antibodies (83% sensitivity, 97% specificity for SLE) and antiphospholipid antibodies, as 30-40% of SLE patients are positive for these 1.
Performance Characteristics
The EULAR/ACR 2019 criteria achieved:
- Sensitivity: 96.1%
- Specificity: 93.4%
This compares favorably to ACR 1997 criteria (82.8% sensitivity, 93.4% specificity) and SLICC 2012 criteria (96.7% sensitivity, 83.7% specificity) 2.
Essential Clinical Warnings
These are classification criteria, not diagnostic criteria 1, 5. They were developed to define homogeneous patient populations for clinical trials and research, not for clinical diagnosis 1. However, they inform diagnostic thinking and provide a structured framework for evaluation 5.
ANA-negative SLE exists but is rare (<5% of cases worldwide) 5. In patients with strong clinical suspicion but negative ANA, consider alternative diagnoses first, but don't absolutely exclude SLE.
Do not use ANA for disease monitoring - it should not be repeated serially to assess disease activity or treatment response 1. Anti-dsDNA and complement levels are more appropriate for monitoring established disease 1.